To the Editor:
The recent observation by Erbs et al 1 that an intracoronary infusion of blood-derived progenitor cells (CPCs) improves LV function after recanalization of a chronic coronary total occlusion (CTO) may represent a new application of cellular therapy for ischemic heart disease. Twenty-six patients underwent PET and SPECT imaging to determine myocardial hibernation 8 days after successful recanalization of their CTO and then received CPCs (69 million; nϭ13) or placebo (cell medium; nϭ13) 2 days later through a PTCA balloon during 4 cycles of 2-minute occlusion and reperfusion. Left ventricular ejection fraction was obtained by cardiac MRI 8 days after recanalization and 3 months later. They noted that the LVEF improved in the CPC group from 52% to 59% with no change in the placebo group. Wall motion score improved from 71 to 77 in the CPC group yet worsened in the Control group (PϽ0.05). The number of hibernating myocardial segments decreased from 2.9ϩ0.6 to 2.0ϩ0.6 at 3 months in the CPC group but increased from 2.6ϩ0.6 to 3.6ϩ0.6 in the Control group at 3 months (PϭNS).
However, the stated benefit of this therapy totally relies on the relative improvement in the CPC group at 3 months compared with a Control group where the LV function did not change and the number of viable segments actually worsened. This lack of improvement in the control group contrasts with many previously published studies 2-6 demonstrating an improvement in LV function in the majority of patients after PTCA of a CTO when the artery remains patent at follow-up. In fact, several of the studies report improvement in LV function that is equal to or greater than that observed in the CPC group. Patients with CTO constitute a very heterogeneous group with regard to collateral circulation and degree of infarction distal to the CTO which could affect the outcome of recanalization attributable to the small sample sizes reported in this study. It is disappointing that the authors did not discuss the lack of improvement in the Control group that made the response in the CPC group appear so robust.
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